Skip to content
The GLP-1 Verdict
Menu

Head-to-head verdict

CoreAge Rx vs Voxy

Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.

Published by The GLP-1 Verdict

Pricing sources checked: CoreAge Rx: August 2026 · Voxy: Check date not recorded

WinnerGrade A · #1

CoreAge Rx

The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.

Visit CoreAge Rx
vs
Grade C · #149

Voxy

Voxy is a Scottsdale, Arizona telehealth practice offering compounded semaglutide and tirzepatide alongside NAD+ and sermorelin.

Visit Voxy

The verdict

Winner: CoreAge Rx

CoreAge Rx takes it with a higher Verdict Score — 94/100 to 71/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Voxy still earns its place — shoppers who want the pharmacy and prescribing group named before they buy.

The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.

Factor by factor

Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.

92Real-world results75
97Price honesty64
96Prescriber access58
88Formulary choice82
95Cancellation fairness70
93Member support79

Price, coverage & features

MetricCoreAge RxVoxy
Verdict Score94/10071/100
GradeAC
Semaglutide$99/moFrom $179/mo (compounded)
Tirzepatide$149/moFrom $299/mo (compounded)
CoverageAll 50 statesNot disclosed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualNoNo

CoreAge Rx

What we like

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation

The caveats

  • Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

Voxy

What we like

  • Names both its compounding pharmacy (VialsRX, Houston TX) and its prescribing medical group (Arora Health & Aesthetics) — most name neither
  • Publishes the full price ladder for both drugs across 1-, 3-, 6- and 12-month terms before you start the assessment
  • One price covers the provider visit, medication, injection supplies, shipping and monthly check-ins — no separate membership fee
  • True month-to-month option at $179 semaglutide / $299 tirzepatide with no commitment required
  • Free assessment with no charge to see if you qualify, and no labs required to start

The caveats

  • No terms of service anywhere on the site — /terms, /terms-of-service and /terms-of-use all return 404
  • No refund policy published; the only stated commitment language is 'cancel anytime'
  • Advertised 'Starting at $129/mo' is the 12-month prepay rate — month-to-month is $179 semaglutide and $299 tirzepatide
  • No public list of states served; availability depends on where affiliated providers are licensed
  • The prescribing nurse practitioner is not named — 'provider details available during your consultation'

Our pick — visit

Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.

Visit CoreAge Rx Read the full CoreAge Rx review →

Also worth a look

Shoppers who want the pharmacy and prescribing group named before they buy.

Visit Voxy Read the full Voxy review →

Keep comparing

Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Voxy does the reverse.

Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.

Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.